Current and Future Applications of Transcriptomics for Discovery in CNS Disease and Injury

Kathryn M. Munro  Victoria M. Perreau
Centre for Neuroscience, The University of Melbourne, Parkville, Vic., Australia

Key Words
Microarray • Transcriptome • Central nervous system • Neural injury • Neural repair • Multiple sclerosis • Spinal cord injury • Traumatic brain injury

Abstract
The central nervous system (CNS) displays heterogeneity at regional, cellular and subcellular levels, making analysis of transcriptomic events accompanying neural injury particularly challenging. Microarray technology provides methods for elucidating global changes in neural gene expression and discovery of signalling pathways within this complex biological network. The lack of suitable and sufficient human CNS tissue along with its inherent variability means that diverse animal models of both multiple sclerosis and neurotrauma are vital for examining the pathophysiological changes accompanying neural injury resulting from disease or trauma. Gene expression profiling of these models is providing valuable information about mechanisms of damage, repair and regeneration and candidate treatments. In vitro models of neural injury are also proving useful, and transcriptomics is enhancing our understanding of the properties of neural stem cells with a view to their therapeutic application in neural repair. Thoughtful experimental design and analysis of microarray experiments is crucial for extracting biological meaning from the vast amount of data produced. In this review we discuss the current and emerging application of transcriptomics for the study of neural function in health, disease and injury.

Introduction
The central nervous system (CNS), which is unique in its temporal and spatial complexity, comprises possibly the most complex system in the human body. It derives much of its complexity from multiple diverse cell types, between which a large proportion of the genome is differentially expressed (DE) [1]. The application of gene expression data to elucidate functional information from such a complex system requires elegant experimental design, generation of vast datasets and analysis tools capable of identifying biologically relevant genes or patterns from within the data.

High-throughput gene expression analysis platforms, such as microarrays, have proven to be powerful tools for generating large amounts of transcriptomic data, and have been embraced by the neurosciences as tools for elucidating function in the healthy and diseased/injured CNS.

Microarray platforms are now in common use for genome-wide analysis of expression changes in diverse experiments investigating mechanisms of neural injury and repair utilising a wide variety of models, as well as in human tissue. These approaches have yielded valuable insight into the molecular signalling pathways involved in neural injury and repair.
such systems. However, in addition to identifying candidate genes, microarrays and other developing technologies are revealing higher orders of complexity in the transcriptome, such as strain-dependent diversity in animal models, revealing big differences in gene expression profiling (GEP) between apparently identical cells and identifying signs of disease in apparently unaffected tissue. As the quantity and complexity of transcriptomic data increases, new analysis approaches are being applied to elucidate biological meaning from the data.

In this review, we will illustrate some of the achievements made through the application of GEP using two very different examples of neural injury: multiple sclerosis (MS) and CNS trauma (traumatic brain injury (TBI) and spinal cord injury (SCI)). Of primary importance in microarray experiments is appropriate design, including controls that provide sufficient leverage to analyse the data with the available tools. Thus, we will discuss some important design and analysis considerations, which are summarised in an experimental design flow chart (fig. 1).

Microarrays were typically applied in many studies as a primary screen or ‘fishing expedition’ to identify one or more DE genes for in-depth follow-up studies. Much of the early-published work was the result of diligent and often laborious analysis of lists of DE genes. Later analyses were improved upon by transcriptional profiles that allow clustering of co-regulated genes. However, these types of analysis are unsatisfactory in the face of increasing data complexity. Recent analysis approaches employing network analysis provide this now matured technology with the capacity to characterise complex gene networks in the CNS. We will discuss how methodological and analysis advances combined with neural injury models or human tissue may improve elucidation of novel signalling pathways involved in response to neural injury and regeneration.
Heterogeneity of the CNS

Structural and Regional Heterogeneity

Transcriptional profiling of 20 different anatomically distinct sites across the human CNS identified both a common underlying expression signature within CNS tissues compared to tissues distinct from the CNS, as well as distinct expression signatures within each CNS region [2]. Not unexpectedly, the cerebellum expression signature was notable for being distinct from all other CNS regions. In addition, this study identified groups of genes specific to different regions, implicating particular molecular functions in the roles of different structures. A recent transcriptome analysis of human brain, examining 3 different regions, leveraged the inherent variability in the samples from 160 individuals to identify networks...
of co-regulated genes [3]. This study also identified consistent expression modules consistently represented across all regions in addition to some expression modules that were expressed in some but not all brain regions. As both these analyses were performed on heterogenous tissue samples, however, the transcriptional complexity produced as a result of cell type-specific gene expression within tissue regions is likely to be under-represented [see Cellular Heterogeneity, pp 314]. Consideration of these differences in regional gene expression is critical with regard to the selection of control tissues for studies involving post-mortem human samples, where uninjured matching regions may not be available [see Human Studies of Neural Disease and Injury, pp 320].

**Cellular Heterogeneity**

For analysis of the transcriptomic response of cell types to neural injury, one must first characterise the transcriptome in healthy cells. Although three main neuronal cell types are commonly discussed in the literature, neurons, oligodendrocytes and astrocytes, there are numerous additional cell types and untold numbers of neuronal cell subtypes in the CNS. Each of these cell types has a unique response to neural injury and capacity for repair. Thus, it is important to characterise the cell-specific transcriptome and response to injury.

In vitro model systems of either primary or immortalised cultures of pure, or mostly pure, cell types have provided transcriptome profiles of the main neural cell types. However, immortalised cell lines are known to behave very differently to cells in the intact animal. Even primary cultures of astrocytes, used to generate GEP, were prepared from neonatal rodent brain and possess an immature or reactive phenotype [4]. In addition to this, the molecular response of a normal cell to injury, for example, is largely governed by interactions with neighbouring cells. To complicate the matter further, many cells project long distances within the CNS; thus, cell–cell interactions can occur over great distances. Furthermore, following certain types of neural injury there is an influx of inflammatory cells, including macrophages, neutrophils, B and T cells, adding to the complexity of cell–cell interactions and molecular signalling. Thus, biological context is crucial to gaining a complete picture of the molecular response of each cell type to neural injury.

To this end, a number of different approaches have been used to characterise the expression signature of distinct neural cell types within their biological context. GEP of selected cells following fluorescence-activated cell sorting (FACS) of neuronal cell types of interest (targeted via expression of a fluorescent protein) was pioneered by Zhang et al. [5], characterising the GEP of touch receptor neurons in *Caenorhabditis elegans*. This methodology has been particularly successful in characterising developmental profiles of cell populations in the brain [6, 7] and spinal cord [8]. This approach was also used to characterise the GEP of neurons and two different populations of astrocytes from murine cortex [9]. A study of astrocytes, neurons and oligodendrocytes purified from developing and mature mouse CNS using FACS analysis provided the first cell-specific transcription profiles for all three primary neural cell types and identified thousands of new genes enriched in particular cell types [10]. The transcriptome of 12 different neuronal populations was analysed using the more gentle technique of hand sorting of fluorescently labelled neurons from defined regions in a number of transgenic mouse lines [1]. These expression signatures were used to generate a taxonomic tree that essentially recapitulated expected relationships between these neuronal subtypes and which also revealed a very high degree of heterogeneity between neuronal subtypes within the same tissue region [1]. Such discrete analyses have also been facilitated by the use of laser capture microdissection (LCM), which has been used for GEP of individual cells of different neuronal subtypes from fixed or frozen sections [11] since the earliest days of LCM technology. LCM has also been combined with a genetically targeted fluorescent label to characterise the GEP of pyramidal motor neurons and pyramidal somatosensory neurons in mouse cortex [12]. There remain some drawbacks with all of the above approaches. Both FACS and hand-sorting methods require live cell purification steps where the transcriptome may be altered in response to stimuli and LCM isolation suffers from contamination by surrounding cells. Additionally, neither sorting nor LCM would preserve neurite arbours of isolated neurons, and both dendritic and axonal processes are now known to harbour their own unique subcellular transcriptomes which respond to extracellular stimuli [13, 14].

Recently, isolation of RNA from genetically targeted neural cell types in vivo was made possible with the development of novel transgenic mouse strains employing translating ribosome affinity purification (TRAP) [15]. Each transgenic mouse line carries a unique bacterial artificial chromosome (BAC) targeting a specific cell type which drives an enhanced green fluorescent protein (EGFP)-L10a ribosomal transgene. The BACs were each chosen for their expression specificity from expression data from the GENSAT database [16] (http://gensat.org/). Consequently, each ‘bacTRAP’ mouse strain selectively
targets a specific cell type or population that is identified by EGFP labelling. The EGFP-L10a transgene is expressed only in the targeted cells and polysomes are purified from tissue homogenates by immunoaffinity purification against EGFP. Immunohistochemistry using antibodies against EGFP can also be used to confirm cell type-specific expression in the bacTRAP mouse line. This approach thus enables the purification of cell-specific polyribosomal RNA while maintaining the vital biological context of the cell. The purified RNA can then be assayed using transcriptomic platforms to generate ‘translational state profiles’ (TSP). As all non-coding RNA (ncRNA) species would be excluded from the dataset, it does not technically represent the transcriptome of the cell. This methodology also overcomes the difficulty of identification and purification of rare and fragile cell types and importantly would include both axonal and dendritic polyribosomal RNA populations.

Using this approach, Doyle et al. [17] generated TSPs from 24 unique CNS cell populations and are making available 16 transgenic lines as a resource for researchers. The bacTRAP mice are a pivotal development for analysis in neurosciences as they overcome many of the design problems encountered in studies of the CNS. They can be used to assess cell-specific responses in whole animal treatments or can be crossed with knockout (KO) mice modelling human disease. In addition to increased specificity, the bacTRAP, cell-targeted TSP is also more sensitive than analysis of homogenous tissue regions, detecting the presence of transcripts not detectable in parallel data from homogenous tissue samples. Doyle et al. [17] calculated that for rare cell types up to 42% of genes enriched in a particular cell type may not be detected at all in microarray studies of the whole tissue region.

Elucidation of cell-specific GEPs via the above approaches is sure to reveal yet more complexity within CNS transcriptomes; they have already shown that the diversity among neuronal subtypes is comparable to that between neurons and glia [17]. Interestingly, the genes with the most variable expression between different cell types are predominantly expressed at the cell surface or are involved in synaptic connectivity [1, 17], supporting the concept that cell–cell communication drives function within the CNS.

Approaches have also been incorporated into GEP analysis methods to account for the varying proportions of different cell types in microarray data from heterogeneous tissue. One approach generated ratios of gene transcript levels between grey matter and adjacent white matter samples to estimate the relative cellular origins of gene expression. Lists of white or grey matter-enhanced genes could then be removed from the analysis, post-hoc, to focus the list of DE genes from cell types predominantly in white or grey matter [18]. Although these analyses were executed without imposing any a priori assumption on the expression pattern of any genes, many genes are commonly expressed in multiple cell types to different degrees. Thus, significant aspects of signalling pathways could be overlooked with this approach. An improved approach has applied network analysis to transcriptome data from 160 human brain control samples and generated modules of co-expressed genes that correlate with neurons, oligodendrocytes and astrocytes [3], [see Conclusions and Future Directions, pp 323].

**Single-Cell Transcriptomes Hint at Higher Levels of Complexity**

Single-cell analysis has been a long-held aim of neuroscientists, and consequently much of the early literature on single-cell transcriptomics relate to the neurosciences. This desire is driven by the need to reveal the behaviour of single cells within the cellular heterogeneity of the CNS. The early uptake of this challenge combined a variety of methods for isolating mRNA from single cells, followed by amplification techniques and combined with microarray analysis [for review, see 19]. For methodological concerns for the application of single-cell transcriptomics to TBI, see Davis et al. [20].

A key finding from single-cell GEP in the CNS and other tissues is the degree of variation between neighbouring, apparently identical cells. LCM of 14 pyramidal neurons from the CA1 region of the rat hippocampus demonstrated a large degree of variation in the transcriptome of neighbouring cells which were apparently identical [21]. LCM was subsequently used to isolate fluorescently-labelled neurons in a rat TBI model, where the expression of the neuroprotective genes, glutathione peroxidase 1, heme oxygenase 1, and brain-derived neurotrophic factor, were found to be significantly decreased in injured CA3 neurons compared with adjacent uninjured neurons [22], demonstrating that transcription signatures of adjacent neurons vary greatly depending upon survival. This variation does not appear to be due to technical noise, suggesting that cellular systems are inherently noisy at the single-cell level [23]. Using murine neural stem cells (NSCs), Subkhankulova et al. [23] determined that the majority of transcripts (44%) are present at less than 25 copies/cell and proposed that this low abundance along with translational regulation may account for the observed heterogeneity.
**RNA Transcript Populations in Subcellular Compartments**

Subcellular mRNA localisation and local translation enables the generation of protein gradients which are essential for cell polarity [24]. Localised protein translation within neurons has been known for some time, and recently a small number of groups overcame technical difficulties to characterise some populations of localised transcripts. Subcellular fractionation methods combined with microarrays were used to characterise transcripts that are localised to RNA granules [25], the synaptosome [25, 26], synaptoneurosomes [26] and postsynaptic density fractions [26, 27]. Microarray analysis has been successfully used on axonal RNA isolated from in vitro cultures using microfluidic chambers [13] or size exclusion membranes [14]. These studies found a diverse range of transcripts in all subcellular populations. Additionally, some populations were shown to respond dramatically to injury [13, 14], neurotrophin treatment [14] or neural activity [25]. An abundance of transcripts for ribosomal subunits were also detected in both dendritic [25] and axonal preparations [13], suggestive of a dynamic capacity to increase translation rates at sites of local protein synthesis. It is important to note that polysomal fractions report TSP as opposed to GEP and RNA granules are sites of RNA silencing; thus, changes in the mRNA profile following neural activity indicate translational repression in dendrites [25].

There remains scope for further elucidation of the regulation of RNA subcellular localisation within neural cells by comparing transcript profiles from different polysomal fractions. The transcript signatures from cytosolic and membrane-bound polysomal fractions have been successfully compared in Hela cells [28]. However, a third polysomal fraction, associated with the cytoskeleton and involved in translation of specific RNA species [29], has not yet been examined. Annexin2 protein is specifically associated with only these cytoskeletal-bound polyribosomes [30] leading to the possibility that immunopurification could be utilised to isolate cytoskeletal-bound polysomes and their associated transcripts. Additionally, RNA-binding proteins are involved in the localisation of transcripts and microarray analysis has shown that they are associated with specific sets of functionally related transcripts, implicated then in the regulatory control of local translation [31–33].

**Transcriptome Complexity**

The presence of ncRNAs in the cellular transcriptome is of increasing relevance. The importance of ncRNA in the CNS was elegantly illustrated by a project that exclusively used expression data from the Allen Brain Atlas to characterise expression profiles of 1,328 transcripts [34]. They found that 64% of the ncRNA transcripts they examined were expressed in the adult mouse brain and the majority of ncRNAs were associated with specific neuroanatomical regions, cell types and compartments. Importantly, when the expression patterns of ncRNA were compared with the associated coding genes, many ncRNA expression patterns overlapped with important CNS-coding genes. MicroRNAs (miRNAs) are 22 nucleotide endogenous ncRNAs that post-transcriptionally repress protein-coding genes by base-pairing to 3’ UTR; at the time of writing, the mouse miRNA database [35] (http://microrna.sanger.ac.uk) contains 9,539 transcripts. Bak et al. [36] profiled expression of all miRNAs in 13 different CNS areas and found that 44 miRNAs displayed threefold enrichment in at least one area. In addition, 50% of miRNAs exhibited different CNS expression patterns compared to zebrafish, demonstrating divergent expression across species.

**Animal Models of Multiple Sclerosis**

MS is a central demyelinating disease resulting in oligodendrocyte death and axonal injury, with an associated progressive and irreversible neurological decline [37]. Its cause is unclear; however, it is generally accepted to be an autoimmune disease involving chronic inflammatory demyelination, and numerous genetic and environmental factors have been implicated in the aetiology of MS [for review, see 38]. The pathophysiology of MS involves oligodendrocyte apoptosis, infiltration of T cells, destruction of myelin by macrophages [39, 40], gliosis and axonal damage [41]. While the cause of the immune-mediated myelin destruction is a source of debate [42], it is believed by many to involve the activation of self-reactive T cells specific for myelin antigens. The course of the disease is variable and presents clinically in several forms: relapsing-remitting, secondary progressive, and primary progressive. Furthermore, inflammatory lesions appearing in the brain and spinal cord are classified into different subtypes based on their pattern of demyelination, suggesting that multiple mechanisms are responsible for demyelination [39, 43]. Transcriptomics has been widely used to investigate this heterogeneous and complex disease through the use of both animal models and studies using patient samples [see Multiple Sclerosis, pp 320].
EAE and Cuprizone Models of Multiple Sclerosis

While there are no animal models that perfectly reproduce this complicated disease [40], two models have been extensively used to examine particular features of the disease and utilised in a number of microarray experiments: experimental autoimmune encephalomyelitis (EAE) and cuprizone intoxication. The pathological features of both EAE and cuprizone vary according to the species, strain and antigen used [44, 45]; gender and age also influence the response to cuprizone [45, 46].

EAE is a model of CNS inflammatory demyelination, induced by inoculation with various CNS myelin antigens or passive transfer of myelin-specific T cells. Although an imperfect model of human MS it shares numerous features such as the presence of multiple inflammatory CNS lesions, making it a useful model for MS research [for review, see 44]. Additionally, clinical disease symptoms such as ascending hindlimb paralysis vary between models, and can have progressive or relapsing-remitting patterns [44]. Over the last decade numerous microarray studies have utilised EAE models with a number of aims; Comabella and Martin [47] reviewed the data up to 2006. Early transcriptome studies identified DE genes associated with EAE progression, constructing a comprehensive profile of the molecular changes occurring in each stage of the disease [48] and identifying genes which may contribute to CNS repair [49]. Other studies analysed the action of potential therapies [50] and identified common DE genes between EAE tissue and human MS lesions [51]. More recent microarray analyses, described below, have continued to augment our understanding of the pathophysiology of EAE.

A temporal profile of DE genes in a relapsing-remitting rat EAE model revealed altered pathways (cholesterol), identified likely pro-regenerative genes, and discovered a highly DE gene (secretory leukocyte peptidase inhibitor, SLPI, ID 84386) previously un-associated with EAE [52]. To assist their analysis, in addition to comparison of gene expression in healthy and affected diseased spinal cords, the authors subtracted genes that were DE in healthy rat lymph nodes thus filtering out DE genes from non-activated infiltrating leukocytes and adding more power to their dataset. They identified that genes involved in the cholesterol biosynthesis pathway were downregulated in all stages of disease; however, genes involved in cholesterol transport were unaltered. Further experiments found no difference in the total cholesterol concentration in spinal cords from control and EAE-affected rats leading the authors to suggest the involvement of a negative feedback loop. This model also enabled the authors to identify a small number of likely pro-regenerative genes that were upregulated in the spinal cord during the recovery phase but not the attack phases. Some genes, such as microtubule-associated protein 2, had previously been associated with CNS repair while other novel genes had not. Finally, expression of secretory leukocyte peptidase inhibitor was upregulated 100-fold in the acute phase and 10-fold in other phases of the disease; protein localisation and in vitro experiments suggested a role in modulation of the immune response and promotion of CNS repair.

KO mice have previously been utilised to investigate genes influencing EAE development and progression [51, 53]. In an effort to identify pathways promoting remyelination, a recent study by Cudrici et al. [53] compared GEPs from the spinal cords of mice deficient in complement component C5, which display severe gliosis and axonal degeneration during chronic EAE, to mice sufficient in C5, which in contrast display extensive remyelination. Genes involved in the insulin-like growth factor and transforming growth factor families were DE, indicating a role of these genes in the detrimental phenotype seen in C5-deficient mice and providing potential future therapeutic targets.

Transcriptomics has identified gene expression changes in cortical grey matter distant from lesions that appeared histologically normal [54]. Microarray analysis of normal-appearing grey matter in the cortex of EAE-affected rats identified numerous DE genes, particularly downregulation of genes encoding mitochondrial proteins; this may be a result of neurodegeneration in the spinal cord [54]. Transcriptional changes in normal-appearing white matter have been demonstrated in the post-mortem brains of human MS patients [55, 56; see Human Studies of Neural Disease and Injury, pp 320]; however, this finding was not recapitulated in an EAE study [54], illustrating the differences that may be seen between human MS and its animal models.

Another widely used animal model of MS is the cuprizone intoxication model [for review, see 57, 58]. Ingestion of the copper chelator cuprizone leads to demyelination of various brain regions, particularly the corpus callosum which presents with a rostral-caudal gradient of pathology [59]. An inflammatory response involving activated microglia and macrophages accompanies the demyelination [60], but in contrast to EAE, there is no disruption to the blood-brain barrier or T-cell infiltration. Importantly, the demyelinating effect of cuprizone is reversible and withdrawal of cuprizone treatment results in spontaneous, progressive remyelination.
Microarray studies have therefore utilised the cuprizone model in an attempt to identify genes and pathways which may be modulated to prevent demyelination and stimulate remyelination after injury, thus protecting the axon [61]. Therefore, the inclusion of multiple time points within experiments is of pivotal importance as genes will be decreasing or increasing depending on the stage of disease. Additionally, some spontaneous remyelination is seen at ~6 weeks despite ongoing cuprizone treatment. This is likely to be due to the proliferation of oligodendrocyte progenitor cells [57].

Studies have examined gene expression changes occurring during cuprizone treatment in vivo, identifying alterations in the expression of genes associated with myelin and inflammation as well as genes associated with diverse functions such as cell signalling and transcription [62, 63]. Microarray results from the cuprizone study by Arnett et al. [63] led to the further characterisation of p8 (also known as nuclear protein 1, ID 56312), a stress-associated gene upregulated during demyelination but not remyelination [64]. Experiments with p8 KO mice confirmed the role of this gene in the exacerbation of demyelination and inflammation; additionally, p8 upregulation was identified in EAE tissue and post-mortem brain tissue from MS patients [64].

The cuprizone model has been employed in combination with transgenic mice to examine the contribution of particular genes to remyelination. Li et al. [65] used microarrays to support their analysis of the role of p53, a pro-apoptotic transcription factor upregulated in the corpus callosum of cuprizone-treated mice. p53 KO mice and mice treated with a p53 inhibitor displayed decreased demyelination and less recruitment of microglia than wild-type (WT) mice; this was reflected in the results of the microarray which revealed higher expression levels of myelin genes and decreased levels of genes related to macrophage and microglial function and cytokine function. Arnett et al. [63] compared gene expression changes in the corpus callosum of WT and tumour necrosis factor-α KO mice, known to have a decreased capacity for remyelination after cuprizone exposure, to identify DE genes in the remyelinating phase which may contribute to this lack of repair. DE genes were associated with cell signalling, transcription and the cell cycle, and the largest category was related to inflammation and the immune response. Genes in the major histocompatibility complex were downregulated in tumour necrosis factor-α KO compared to WT mice during the remyelinating phase, and further experiments confirmed the upregulation of major histocompatibility complex II following cuprizone treatment affected oligodendrocyte regeneration and the rate of remyelination.

Animal Models of Traumatic Brain Injury and Spinal Cord Injury

The pathology of human TBI and SCI is complex, and varies depending on the type and severity of injury. The initial trauma sets in motion a variety of events which lead to further damage. Well-characterised components of neurotrauma include blood-brain barrier disruption, infiltration of inflammatory cells, astrogliosis and glial scar formation, excitotoxicity, cell death and axonal degeneration; tissue atrophy may continue many months after the injury [for review, see 66]. As well as the focal area of damage caused by TBI, the mechanical force of injury itself can disrupt axonal membranes resulting in axonal injury and affecting the survival of neurons [67].

As described for MS, microarray studies attempting to elucidate the molecular responses to neurotrauma have utilised a range of animal models. Commonly used models of TBI include controlled cortical impact, weight drop, impact acceleration and fluid percussion [for review, see 68]. These models result in focal injury (cortical controlled impact, weight drop), diffuse injury (impact acceleration) or a combination (fluid percussion). Another model of TBI, cryoinjury, involves application of dry ice to the skull. Similarly, different SCI animal models are utilised; while a crush or contusion model of injury most accurately resembles human SCI, trans-section models can reliably sever spinal cord axons and provide an accurate evaluation of axonal regeneration [69]. Transcriptome studies are affected by the species, strain and model of neurotrauma used and are thus an important consideration for design (fig. 1). General differences in rat and mouse SCI models include the formation of either a cavity (rats) or fibrosis (mice) at the lesion centre, and differences in the inflammatory response [70]. Strain differences were demonstrated in a microarray study comparing the response to contusion injury in three common strains of rat which exhibited different functional outcomes [71]. The genetic background of rodents can affect the extent of neural regeneration [72] and wound healing [73]. However, different strains cannot simply be presumed to have a significant difference in GEP after injury; a study comparing two rat strains known to have different inflammatory and recovery responses after contusion found a relatively small number of DE genes
between them over an extended period of time after injury, emphasising the fact that regulation of transcript levels are only a small part of regulatory responses following injury [74].

**Traumatic Brain Injury**

The early uptake of microarray technology led to significant advancements in the understanding of the molecular cascades initiated following TBI [for review, see 75, 76]. These studies have identified numerous variables that have large effects on the molecular responses to injury. Cumulatively, these studies have examined the general pathological and protective mechanisms involved in primary and secondary injury [77]; determined how different areas of the brain including the cortex [78–80], hippocampus [81, 82] and subventricular zone (SVZ) [83] respond to TBI, and discovered differential gene expression as a consequence of injury severity [84]. Despite the differences expected between strains and models of TBI, the alteration of many genes after injury has been shown to be consistent [85]. The temporal effects on molecular changes following injury have been examined in countless studies. Temporal delays in gene expression changes can occur; conversely, altered genes, including transcription factors whose expression is induced minutes or hours after injury, may return to control levels within 24 h [76]. Hierarchical clustering of genes with similar expression patterns after injury – particularly at different time points after injury – is helpful for determining common pathways or upstream regulators that contribute to the change in transcription [76].

As in MS studies, transgenic mouse lines have been utilised to examine the impact of particular genes on the global response to TBI. Two studies have examined the transcriptome response to cytokine in mice which have altered levels of the cytokine interleukin-6 (IL-6), an inflammatory mediator known to have significant and wide-ranging effects on the response to neurotrauma. The first used IL-6 KO mice which have a worse than usual response to TBI [86], and the second used transgenic mice which produce IL-6 in astrocytes and are known to have less cell death and increased repair after TBI [87]. IL-6 KO mice had a substantially different response at 1 day after injury compared to WT controls, with a tendency for attenuated upregulation of multiple transcription factors; the authors suggest it is this early transcriptional difference that underscores the later poor recovery from TBI [86]. Mice producing IL-6 in astrocytes had increased expression of inflammatory genes compared to WT controls, as expected; they also had decreased expression of pro-apoptotic genes and changes in genes associated with a wide range of processes including oxidative stress, synaptic activity, and cell migration and proliferation [87], thus demonstrating the pervasive nature of IL-6 signalling following injury. In another example, recent studies have conducted microarray analyses of TBI using mouse models of Alzheimer’s disease [88, 89]. In one study [89], mice expressing the human apolipoprotein E (APOE) gene isoform APOE4, previously associated with a poorer outcome after TBI, were compared with APOE3 mice 4 weeks after receiving a controlled cortical impact. APOE4 mice had far fewer DE genes in the hippocampus and cortex compared to APOE3 mice at this time point. Fewer genes associated with the immune response, cellular movement and cell–cell signalling and interaction were observed in the APOE4 mice, among other categories. This led the authors to suggest that APOE4 mice fared worse after TBI because of the gene expression changes and post-injury mechanisms they were lacking, and not because of increased neurodegenerative mechanisms as had been expected, thus illustrating the advantage of observing global gene expression changes with microarray technology.

There are currently no effective therapeutic treatments for TBI; however, the efficacies of candidate therapies are being tested in vivo and GEP is assisting in revealing their mechanism of action. FG loop (FGL) is a peptide derived from the neural cell adhesion molecule that is neuroprotective in an ischemic model of TBI [90] and induces neurite outgrowth in vitro [91]. Pedersen et al. [92] examined the effect of FGL treatment of cryoleisioned rats using GEP across 2 time points and identified 4 clusters of genes responsive to the interaction effect of FGL and TBI. These clusters indicated involvement of diverse pathways implicated the Fas apoptotic inhibitory molecule (FAIM, ID 140930) in the neuroprotective contribution of FGL. Minocycline is an anti-inflammatory agent that reduces the volume of secondary injury 24 h after lesion and is currently of interest as a potential neuroprotective treatment; however, the biological processes it acts upon are unknown. Crack et al. [93] administered minocycline to mice injured using a weight drop model. They identified potential effects of minocycline on a large number of diverse pathways including astrogliosis. They also, unexpectedly, found that in TBI minocycline up-regulated the pro-apoptotic genes caspase-3 (CASP3, ID 12367) and caspase-8 (CASP8, ID 12370), implicating minocycline in activation of cell death pathways. This study also revealed the involvement of many more inflammatory molecules in TBI than previously supposed.
A recent study examined changes to miRNA expression in rat hippocampus after controlled cortical impact detected alterations in 85 of 444 miRNAs examined [94]. These transcripts were predicted to target a wide variety of genes involved in general and essential roles such as transcription, signal transduction and proliferation. The discovery that DE miRNAs are part of the transcriptome in two-dimensional experiment demonstrated the temporal and spatial complexity of gene expression changes and identified affected regulatory pathways in multiple affected systems, including: inflammation, complement cascade, vasculature and angiogenesis, cholesterol biosynthesis, cell death, calcium signalling, and synaptic plasticity. A subsequent study by De Biase et al. [96] additionally examined the effects of mild, moderate and severe contusion. They showed that gene expression responses following mild injury were relatively rapid, whereas they were delayed and prolonged after severe injury.

The ultimate aim of SCI research is neural regeneration leading to functional recovery. Microarray technology is being applied to different models of neural regeneration including in vitro models of neurite outgrowth [97], and in vivo analyses of injury in the peripheral nervous system, where repair can occur [98, 99]. Identification of conserved genes which are similarly or differentially expressed after injury in regenerating compared to non-regenerating animals may help elucidate genes important to this response; thus, animals that naturally exhibit CNS regeneration after injury, such as the immaturity Monodelphis domestica [100] and salamander [101], are therefore of particular interest. Such approaches are illustrated by a study using a small-scale array of inflammatory genes implicating them in the regenerative capacity of M. domestica [100]. Monaghan et al. [101] used a custom-made microarray chip to examine early gene expression changes following SCI in salamanders, which display regeneration and functional recovery after tail amputation. Numerous genes known to be upregulated in mammals after injury were similarly upregulated in the salamander, including jun B proto-ocogene (JUNB, ID 3726), APOE (ID 107741), heme oxygenase 1 (HMOX1, ID 3162), and genes involved in the immune response. Conversely, several genes associated with glutamate metabolism and transport were downregulated in the salamander after injury, contrary to the response expected in mammals. Mona-ghan et al. [101] compared their gene list with previously published rat SCI studies; several genes DE in the salamander only had previously been linked to injury in other regenerating animals (e.g. amphibians). The use of such models for transcriptomics has been limited until recently due to the availability of species-specific arrays; however, the advent of high-throughput sequencing will enable further studies to be undertaken.

Human Studies of Neural Disease and Injury

In addition to the heterogeneity of MS and neurotrauma, gene expression changes in the human brain are also dependent on both age and gender [102]. The tissues available for microarray analysis include post-mortem CNS tissue (or brain biopsy tissue in a small number of cases), cerebrospinal fluid and blood.

Multiple Sclerosis

As mentioned in Animal Models of Multiple Sclerosis [pp 316], MS is a complex neural disease with different clinical forms, and transcriptomic research approaches were embraced with the hope of identifying factors influencing disease susceptibility. Early studies indicated a significant genetic factor in susceptibility to disease, and thus both large genotype studies and expression profiling studies have been conducted in efforts to elucidate the genes affected. Microarray studies relating to MS are diverse and pose a variety of biological and clinical questions. Studies using tissues such as peripheral blood mononuclear cells aim to identify biomarkers to aid diagnosis, predict disease course and examine patient responses to treatment. Analysis of peripheral blood mononuclear cells is particularly popular for research into MS; however, as it does not directly relate to neural injury, it is not discussed here. Post-mortem brain tissue has been used to identify molecular changes in healthy versus diseased tissue, and has de-
tected DE genes in lesions classified as acute, chronic active and chronic inactive [103–105].

Gene expression analysis has identified mitochondrial dysfunction as a contributing factor to the pathogenesis of MS [106]. Dutta et al. [106] compared non-lesioned motor cortex tissue from MS patients with severe disabilities to tissue from matched controls without neurological disease. DE genes were associated with processes including oxidative phosphorylation, synaptic transmission and cellular transport. Notably, 26 genes associated with the mitochondrial electron transport chain were downregulated in the motor cortex of MS patients. Further experiments confirmed that the function of mitochondrial respiratory chain complexes I and III were downregulated when controlling for variables in human TBI, in- cluding age, gender, ethnicity, type and severity of injury, time elapsed since injury, pharmacological intervention, alcohol consumption, anaesthetics, and appropriate control samples. The same concerns relate to studies on spinal cord tissue from human SCI patients for which no transcriptomic studies could be identified.

**Employing Stem Cells in Neural Regeneration**

Stem cells and progenitor cells are areas of intense research as potential therapeutics for neural repair [for review, see 108]. Stem cells can give rise to neural progenitor and neural precursor cells, which can be manipulated in vitro and grafted into the injured CNS. Consequently, implanted NSCs are being investigated for their capacity to replace missing and damaged cells [109]. It is also envisaged that the migratory properties of NSCs may make them suitable vehicles for gene therapy delivery [110] and that neurogenesis within endogenous adult NSC populations could be manipulated to assist repair and regeneration of the CNS [111]. GEP is enabling a better understanding of stem and progenitor cell differentiation, accurate staging and identification of cell lines, and addressing some of the fundamental questions in NSC biology that need to be answered before such approaches can be realised. Genes, proteins and signalling pathways involved in stages of cell differentiation are being defined in vitro, as well as how these characteristics can be manipulated by cell culture conditions [112, 113]. Examples of recent studies are described below.

Numerous studies have used microarrays to examine the changes in gene expression as NSCs go through stages of differentiation [112, 114–116]. Cai et al. [112] looked at the in vitro method of ‘priming’ cultured human NSCs, which causes the cells to differentiate into neurons (rather than astrocytes) when grafted into the adult CNS [117]. To examine how neural priming varied from the normal process of neural differentiation, they first compared primed and unprimed cells at various time points, before going on to compare unprimed, differentiated human NSCs with cells that had first been primed and then differentiated. This enabled them to identify the altered genes and pathways which ultimately led to a different cell phenotype (these included Notch, Wnt, and trimeric G protein pathways) and provided valuable information about the mechanisms involved in the priming and differentiation of human NSCs in vitro, and how to direct NSCs to differentiate into neurons after implantation.

Obayashi et al. [113] used microarray technology to address the issue of neural progenitor cells differentiating into astrocytes following implantation in the CNS, an
unwanted outcome which may contribute to astrogliosis. They examined gene expression differences in human neural progenitor cells cultured with and without serum conditions known to promote astrocyte differentiation. Analysis of relevant genes combined with further experiments enabled them to identify a component of the serum, BMP4, which is likely to play a major role in inducing astrocyte differentiation. The gene expression data also allowed them to form a hypothesis about the gene interactions that leads to BMP4 induction of astrocyte differentiation.

GEP has been used to characterise a common stem cell gene expression signature within stem cells from lateral ventricle wall tissue, neurospheres and another stem cell line [118]. Conversely, GEP has also shown that phenotypically identical NSCs may, in fact, differ in their GEPs. This finding is supported by transcriptomic data from Kelly et al. [119] who compared embryonic mouse NSCs derived from the cortex and spinal cord, and found that although they shared similar properties when cultured, each NSC type retained some differences in gene expression. Such information is crucial for determining the most appropriate source of NSCs to repair particular regions of the CNS.

Regenerating oligodendrocytes could potentially reverse the demyelination and axonal degeneration in MS due to oligodendrocyte apoptosis, and it has been postulated that the multipotential neural precursor cells that reside within the SVZ could provide a source to replace lost oligodendrocytes following demyelination [120, 121]. Thus, there is intense interest in understanding the endogenous mechanisms regulating their development. Recently, a network analysis using numerous normal human tissue samples identified a module of genes with co-regulated expression in a tissue region that included the SVZ. Scrutiny of this model identified genes known to correlate with astrocytic expression and the authors surmised it to be a gene expression module for the adult subventricular neurogenic niche. This list may therefore include genes that are involved in NSC development or migration, however, not necessarily from a single-cell type as a number of cell types are presumed to be involved in the process.

**In vitro Models of Neural Injury**

Although it has been known for some time that protein synthesis occurs in dendrites [122], developing axons [123] and growth cones of adult sensory axons [124], it was not until recently that the diversity of the transcript populations within these subcellular compartments was realised.

Taylor et al. developed microfluidic technology for isolating axonally localised transcripts [125] and demonstrated for the first time the presence of >300 different types of mRNA transcripts localised in the axons of mature cortical axons [13]. They also used this approach to measure changes in the abundance of axonally localised transcripts following axotomy. They found that 2 days after axotomy, 866 transcripts (20%) changed in abundance relative to naive axons, roughly equally distributed between increased and decreased transcripts. Gene ontology groups that were identified as increased included: cell differentiation, cell–cell signalling and secretion, all of which support axonal targeting and synaptic function. The presence of transcripts for translational machinery was notable for abundance in uninjured axons, however, it was not significantly changed following injury suggesting that translation rate per se is not altered. Furthermore, decreased localisation of transcripts involved in the electron transport chain suggests that injured neurons may re-grow in a more glycolytic mode [13].

It is interesting to compare these recent data with those of Willis et al. [14] who isolated axonal RNA from dissociated cultures of dorsal root ganglion neurons following 2 days of in vitro culture. These cultures had been preconditioned by sciatic nerve crush 7 days prior to culture. They identified >200 different transcripts as being present in the axonal RNA preparations and 91 of these transcripts were also localised to naive cortical axons [13], suggesting a high level of similarity between cortical and peripheral axons. However, since both these studies utilised an in vitro model, one must question whether this resembles the in vivo state of axons. Local synthesis of proteins occurs rapidly following axotomy, peaking at 1 h [126], suggesting localisation of mRNA ready for translation. Although Taylor et al. [13] showed that the cortical axonal RNA pool undergoes a rapid transition within 2 days of injury to supply protein synthesis demands, Willis et al. [14] showed that >90% of the axonal RNA population is replaced over a 4-hour period of stimulation, thus revealing a highly dynamic process of axonal RNA localisation. Notably, Willis et al. [14] also demonstrated using qPCR that numerous transcripts respond dramatically in response to neurotrophins.
Conclusions and Future Directions

Although microarray platforms have revealed daunting levels of complexity, they are incapable of surveying the true content and complexity of the transcriptome. High-throughput sequencing, however, is not constrained by current knowledge or prescriptive in design. Recent technological advances have enabled high-throughput sequencing analysis of single cells and has revealed yet more variation in the transcriptome. Single-cell mRNA-seq assay using ABI SOLiD sequencing on a single mouse blastomere identified 75% more transcripts (5,270) than was detected by a parallel microarray using 80 pooled 4-cell embryos [127]. In addition to detecting many more transcripts, this study also identified 1,753 new splice junctions. This is comparable to a recent high-throughput sequencing study on heterogenous tissue which detected up to 11,000 new splice junctions across 6 different tissues and estimated that 95% of multiexon genes undergo alternative splicing [128]. High-throughput sequencing of undifferentiated embryonic stem cells also revealed a high level of novel transcript variants [129]. Transcriptome analysis using high-throughput sequencing of single cells comparing oocytes lacking components of miRNA processing machinery identified over 1,000 deregulated transcripts [127], demonstrating that miRNA plays an important and diverse role in regulation of the transcriptome. A recent novel finding is that a significant proportion of the transcriptome may also be made up of repeat elements [129]. Single-cell transcriptome analysis has recently been facilitated by the application of microfluidics to methodological problems of isolating cytoplasm for single-cell analysis [130, 131], resulting in the detection of 5,000 genes in a single neuron. Thus, although transcriptomic analysis using microarrays has enabled significant progress in our understanding of transcriptomic regulation in the CNS, it is clear that our current picture of transcriptional complexity is grossly simplified. The contribution of multiple splice variants, long ncRNA and miRNA, to the complexity of the CNS has barely been touched upon to date.

As microarray platforms have evolved to the level of whole genome analysis, the sophistication of analysis methods has similarly evolved. In particular, various types of network analysis are proving valuable in elucidating molecular signalling mechanisms from expression data. Critical molecules in biological pathways, such as kinases, may not exhibit expression changes at the transcriptional level, thus combining gene expression data with network data on interacting proteins and canonical pathway analysis is useful in identifying activated signalling pathways that would otherwise be missed or down weighted. Other network approaches analyse co-expressed genes which have similar profiles across a number of samples to identify ‘modules’ of related genes/molecular components. Using this approach, Oldham et al. [3] showed that the cortical transcriptome is organised into a number of robust modules that are conserved among individuals. They went on to identify a number of interconnected transcriptional models representing distinct organelles, synapses, cell types and possibly a module characterising the adult subventricular neurogenic niche [3]. This type of analysis utilised ‘differential network analysis’ effectively normalising each sample and controlling for sources of variance arising from biological and technical factors. Therefore, this approach may assist in overcoming significant design problems encountered when using human CNS trauma samples. The organisation of the brain transcriptome in such a way may provide a foundation for identifying perturbation to modules as a result of disease or injury.

A network approach can also be used to capture functional differences in small networks of related genes. Palacios et al. [132] applied network analysis to a small starting set of only 20 genes known to be involved in the immune system. Expression profiling in 52 MS patients and matched controls identified JAGGED1 (JAG1, ID 182) as an important regulator in T-cell activation whose activity was incompletely restored by interferon treatment and thus is a potential therapeutic target for autoimmune disease (MS) [132].

In addition to defining molecular pathways both within and between CNS cells, a detailed knowledge of the interconnecting pathways, neural circuits, is also lacking. We have very little understanding of how long-distance circuits involving multiple regions of the CNS orchestrate brain function, mental and behavioural outcomes. Disruption of this circuitry is a major cause of dysfunction following neural injury. An understanding of these pathways, ‘the connectome’, will lead to a better understanding of the impact of CNS injury on their disruption and may lead to improved therapies. The development of ‘brainbow’ mice allows the identification of the destination of an axon simply by a unique colour, thus making it possible to trace some long wiring connections in mammalian CNS [133]. These and other innovations lead to the exciting possibility that it may soon be possible to characterise the transcriptome of both a neuron and the cell it innervates in an in vivo model.
Transcription analysis of neural injury has provided a glimpse of the complexity of the molecular signalling involved in the CNS response to injury, and yet a relatively small number of signalling pathways modulated in neural injury have been studied in any detail. Genome-wide transcriptomic data sets have the capacity to reveal much more in spite of the growing realisation that measurements of transcript abundance reflect only one small component and signalling instructions enabling research-ers to describe cell type-specific, cell–cell interaction and sub-cellular population responses. From the vast amounts of data generated by high-throughput technologies, analyses would define patterns or modules of molecular components and signalling instructions enabling researchers to describe biological and physiological responses in meaningful terms.

References

Applications of Transcriptomics for Discovery in CNS Disease and Injury

46 Irvine KA, Blakemore WF: Age increases axon loss associated with primary demyelination in cuprizone-induced demyelination in C57BL/6 mice. J Neuroimmunol 2006;175:69–76.


Applications of Transcriptomics for Discovery in CNS Disease and Injury